(NewsDirect)
Emyria Ltd (ASX:EMD)MD Michael Winlo tells Proactive the company has secured animmediately available local supply of MDMA, the final component thatallows patient dosing to commence for its MDMA-assisted therapy trialto treat post-traumatic stress disorder (PTSD). The locally availableMDMA will be supplied to Emyria through a collaboration with MindMedicine Australia (MMA) and the Australian National University (ANU).This supply ensures the company can commence its ethics-approvedMDMA-assisted therapy (MDMA-AT) trial while it awaits Health Canada toapprove a comprehensive MDMA shipment from Canada.
Winlo said: "Withour recent milestones, including the Pax Centre acquisition, ourteam's training and ethics approval, MDMA supply was the finalcomponent.
“Weare grateful to MMA and the ANU for their support in securing animmediately available initial supply which ensures we can continueprogress while we wait for our subsequent larger shipment from Canadapending approval from Health Canada.”
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.